Clinical evidence
PromarkerEso's ability to diagnose disease early in patients was validated in multiple clinical studies
Esophageal cancer diagnostic excels with 94% accuracy in clinical validation study
In the primary clinical validation study, PromarkerEso showed accuracy of 94% in both determining patients as having EAC, or not having EAC. The area under the receiver operating characteristic curve (AUC) was 0.93, sensitivity 93.1%, with a low false positive rate (3.4%), and specificity 96.6% with high “rule-out” capability (NPV = 93.8%).
Poster. S. Bringans, J. Sheahan, K. Peters, I. Wang, M.N. Duong, G. Dhamrait, R. Lipscombe. 20thISDE World Congress for Esophageal Diseases in Edinburgh, Sep 2024.
Poster.S. Bringans, E. Schoeman, N. Dorta Scott, R.Wang, P.Galettis R. Lipscombe. 29thAnnual Proteomics Lorne Symposium in Lorne, Australia, 31 January – 3 February 2024.
Oral Presented by R. Lipscombe. R. Lipscombe M.N. Duong, R. Casey, G. Fernadez, S. Bringans, K. Peters, M.M. Hill, P. Tan, L. Chen.19th ISDE World Congress for Esophageal Diseases in Toronto, September 2023.
A.K Shah, G. Hartel, I. Brown, C. Winterford, R. Na, K. Le Cao, B.A. Spicer, M.A. Dunstone, W.A. Phillips, R.V. Lord, A.P. Barbour, D.I. Watson, V. Joshi, D.C. Whiteman, M.M. Hill; Mol Cell Proteomics 2018; 17(12): 2324–2334.
